mesoridazine

Trade name: serentil

Small moleculeapproved

Approved

Feb 27, 1970

Mesoridazine (brand name Serentil) is a phenothiazine antipsychotic. It was marketed in the U.S. for the treatment of schizophrenia, behavioral problems in mental deficiency and chronic brain syndrome, alcoholism and psychoneurotic symptoms, such as anxiety and tension. Due to the risk of serious cardiac events the indicated use of Serentil was limited to severely ill schizophrenic patients who fail other therapies. Based upon animal studies, mesoridazine acts indirectly on reticular formation, whereby neuronal activity into reticular formation is reduced without affecting its intrinsic ability to activate the cerebral cortex. Mesoridazine shows a moderate adrenergic blocking activity in vitro and in vivo and antagonizes 5-hydroxytryptamine in vivo. — NCATS

Clinical trial activity

0 trials · 0 clinical orgs · 1 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Timeline

1970s

Feb 27, 1970
Novartis — Earliest FDA Approval
Feb 27, 1970
Novartis — NDA Secondary Org
Feb 27, 1970
Novartis — NDA Organization

Indications

Approved for

Mechanism of action

Serotonin 2a (5-HT2a) receptorANTAGONIST
HTR2A antagonist
- 5-hydroxytryptamine receptor 2A (HTR2A) ↗
Dopamine D2 receptorANTAGONIST
DRD2 antagonist
- D(2) dopamine receptor (DRD2) ↗

Approval history

approvedFeb 27, 1970

Chemistry & pharmacology

Loading structure…

SMILES

CN1CCCCC1CCN1c2ccccc2Sc2ccc([S+](C)[O-])cc21

Mol. weight: 386.59 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Racemic Mixture
Inorganic: No
Polymer: No
Delivery: Oral, Parenteral
Availability: Discontinued

Oral

Yes

Parenteral

Yes

Topical

Black box warning

Sources

Also known as

10-(2-(1-methyl-2-piperidyl)ethyl)-2-methylsulfinyl phenothiazine
10-(2-(1-methyl-2-piperidyl)ethyl)-2-methylsulfinyl phenothiazine
10-(2(1-methyl-2-piperidyl)ethyl)-2-(methylsulfinyl)phenothiazine
10-(2(1-methyl-2-piperidyl)ethyl)-2-(methylsulfinyl)phenothiazine
2-methanesulfinyl-10-[2-(1-methyl-piperidin-2-yl)-ethyl]-10h-phenothiazine
2-methanesulfinyl-10-[2-(1-methyl-piperidin-2-yl)-ethyl]-10h-phenothiazine
lidanar
lidanar
mesoridazina
mesoridazina
mesoridazine
mesoridazine
mesoridazine
mesoridazine
mesoridazine
mesoridazine
mesoridazine
mesoridazine
mesoridazine besilate
mesoridazine besilate
mesoridazine besilate
mesoridazine besilate
mesoridazine besilate
mesoridazine besilate
mesoridazine besylate
mesoridazine besylate
mesoridazine besylate
mesoridazine besylate
mesoridazinum
mesoridazinum
nc-123
nc-123
serentil
serentil
serentil
thioridazine-2-sulfoxide
thioridazine-2-sulfoxide
thioridazine-2-sulfoxide
thioridazine thiomethyl sulfoxide
thioridazine thiomethyl sulfoxide
tps-23
tps-23
tps-23

Organizations

Marketing (2)

Organization	Org type	Relationship	Date
Novartis	For profit	NDA2	Feb 27, 1970
Novartis	For profit	NDA	Feb 27, 1970